Therapeutic Antibodies for Infectious Diseases: Recent Past, Present, and Future

Area of Science:

• Infectious disease research
• Vaccinology
• Immunotherapy

Background:

• Preventive vaccines are a primary goal in infectious disease research.
• Therapeutic interventions are crucial for mitigating disease spread when vaccines are not yet available or in development.
• The COVID-19 pandemic highlighted the need for rapid development of effective treatments.

Purpose of the Study:

• To review the recent history of therapeutic antibody use for infectious diseases.
• To highlight antibodies utilized in COVID-19 treatment over the past five years.
• To discuss challenges in rapid antibody development during pandemics and explore AI-driven solutions.

Main Methods:

• Literature review of therapeutic antibody applications in infectious diseases.
• Focus on antibodies used for COVID-19 treatment within the last five years.
• Exploration of emerging technologies, specifically AI-driven design, for protein therapies.

Main Results:

• Therapeutic antibodies have played a significant role in managing infectious diseases, particularly COVID-19.
• Challenges exist in the rapid development and deployment of antibodies during pandemic outbreaks.
• AI-driven design presents a promising avenue for accelerating the creation of novel protein therapies.

Conclusions:

• Therapeutic antibodies are vital for controlling infectious disease transmission.
• Overcoming challenges in rapid antibody development is essential for pandemic preparedness.
• Artificial intelligence holds potential for revolutionizing the design of protein-based therapeutics.